Logo

Astellas and Seattle Genetics' Padcev (enfortumab vedotin-ejfv) + Keytruda Receive FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Bladder Cancer

Share this
Astellas and Seattle Genetics' Padcev (enfortumab vedotin-ejfv) + Keytruda Receive FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Bladder Cancer

Astellas and Seattle Genetics' Padcev (enfortumab vedotin-ejfv) + Keytruda Receive FDA's Breakthrough Therapy Designation as 1L Treatment for Advanced Bladder Cancer

Shots:

  • The BT designation is based on P-Ib/II EV-103 study assessing Padcev + Keytruda (pembrolizumab) in patients with LA/ mUC who are unable to receive cisplatin-based CT treated in the 1L setting
  • The FDA's BT designation expedite the development and review of drugs that are intended to treat a serious or life-threatening condition
  • Padcev is an ADC targeting Nectin 4 and has received the US FDA’s approval in Dec’2019- indicated for LA/mUC in patients prior treated with PD-1/PD-L1 and platinum-containing CT before & after surgery

Click here ­to­ read full press release/ article | Ref: Astellas | Image: The Pharma letter


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions